June 2024 - Congratulations to Genesys Partner and CFO Jennifer Williams on being appointed to the Board of the Canadian Venture Capital & Private Equity Association (CVCA)! Proud to have Genesys Capital represented!
MAY 29, 2024 - Toronto-based Genesys Capital won the 2024 VC Deal of the Year award for its investment in Montréal-based Inversago Pharma. Gensys led Inversago's $7-million Series A round in 2018 which led to a $1.4 billion CAD acquisition by Novo Nordisk in August 2023.
SUDBURY, ON, Mar 19, 2024 — Flosonics Medical, a leader in wearable medical ultrasound has announced Series C financing of $20 million USD. The round was led by New Leaf Venture Partners, with participation from previous investors Arboretum Ventures, Genesys Capital, and iGan Partners. This new funding will support Flosonics as the company continues to innovate and drive market adoption of FloPatch, a first-in-class wearable Doppler ultrasound for hemodynamic assessments.
HAMILTON, ON and BOSTON, USA, March 19, 2024 -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive agreement to be acquired by AstraZeneca. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
TORONTO, Feb 27, 2024 — Profound Medical Corp, a commercial-stage medical device company that develops and markets customizable, incision-free therapies for ablation of diseased tissue, has announced it has entered into a non-exclusive collaboration with Siemens Healthineers, a global leader in medical technology. The collaboration aims to lay the groundwork for Profound to market a complete therapeutics solution, combining its TULSA-PRO® system with the MAGNETOM Free.Max magnetic resonance (“MR”) scanner from Siemens Healthineers, via Profound’s own sales force.
HAMILTON and BOSTON, Feb 16, 2024 — Fusion Pharmaceuticals Inc., a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines, announced it has entered an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors"). The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers.
MONTREAL, Jan 2024 — CLINICAL TRIAL UPDATES ON INV-202 and INV-347 — Novo Nordisk has initiated a phase 1 trial with a next-generation oral small molecule CB1 receptor blocker INV-347, investigating its safety, tolerability and pharmacokinetics. In the second half of 2023, Novo Nordisk also initiated a phase 2 trial in people with obesity with INV-202. INV-202 is also an oral small molecule CB1 receptor blocker, and is currently in phase 2 for diabetic kidney disease. Both INV-202 trials are expected to complete in the second half of 2025. All trials are conducted by Inversago Pharma, which was acquired by Novo Nordisk in 2023.
HAMILTON and BOSTON, Jan 4, 2024 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines, announced significant progress with its FPI-2265 development program, an update on FPI-1434 Phase 1 Cohort 2 data, and the production of the first clinical doses at the Company's proprietary manufacturing facility.
HAMILTON and BOSTON, Nov 16, 2023 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), announced that the companies have entered into a new agreement for supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.
HAMILTON and BOSTON, Oct 16, 2023 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines, announced the appointment of Jeremy Bender, Ph.D., M.B.A., Teresa Bitetti, M.B.A., and David Meek to its Board of Directors, effective today.
HAMILTON and BOSTON, Oct 12, 2023 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines, has announced the presentation of preclinical data for FPI-2068, a clinical stage bispecific IgG-based targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that co-express EGFR-cMET. Fusion is jointly developing FPI-2068 with AstraZeneca (LSE/STO/Nasdaq: AZN) under the companies' multi-asset collaboration agreement. The data are being presented in a poster presentation at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, Massachusetts.
TORONTO, Sept 25, 2023 — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, has announced it has received 510(k) clearance from the U.S. Food and Drug Administration FDA for the Company’s Thermal Boost module for use in conjunction with TULSA-PRO®.
RIVERSIDE, CA, Sept 21, 2023 — Riverside University Health System has announced the implementation of FloPatch™ by Flosonics Medical. A pioneer in adopting new, ground-breaking medical technology, Riverside says the move makes a significant leap forward in healthcare innovation, particularly in the life-saving area of sepsis management.
FloPatch™ is a revolutionary tool that facilitates real-time precision in IV fluid management in sepsis. The FDA-cleared, wireless, wearable, point-of-care, Doppler ultrasound system empowers clinicians to accurately assess patients and determine the most appropriate therapeutic intervention.
Carlsbad, CA, Sept 5, 2023 – Palisade Bio Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, has announced it has entered into a licensing agreement with Giiant Pharma. The license provides Palisade with exclusive worldwide rights to develop, manufacture, and commercialize Giiant’s proprietary targeted prodrug platform focused on therapies for the multi-billion dollar IBD market.
Ottawa, Jul 27, 2023 — CryoStasis Inc. has announced it has secured Seed financing to pursue its development of next generation sub-zero unfrozen cryopreservation solutions. The company’s first financing round was led by Genesys Capital with significant participation from individual investors and the management team.
PHILADELPHIA — Researchers from Toronto's University Health Network (UHN) have presented results using the Cryostasis platform to successfully transplant porcine kidneys preserved at below zero degrees C for 24 hrs, achieving full recovery with normal kidney function in all transplantations. The breakthrough results were presented at the American Society of Nephrology Annual Meeting in Philadelphia.
HAMILTON, ON and BOSTON, June 26, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of interim data from the dose escalation portion of the Phase 1 trial...
Montreal, Canada and San Diego, CA – June 23, 2023 – Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers...
FREDERICK, Md., June 20, 2023 (GLOBE NEWSWIRE) — Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies...
TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, with sponsorship and support from multiple physician specialty societies...
MOUNTAIN VIEW, Calif., March 14, 2023 /PRNewswire/ — El Camino Health is the first health system in the world to adopt FloPatch, an innovative new technology that monitors blood flow in real time. Developed by Flosonics Medical, FloPatch is the world's first wireless, wearable Doppler ultra-sound system that helps clinicians better manage intravenous (IV) fluid therapy earlier in the sepsis care pathway.
MONTREAL–(BUSINESS WIRE) – FEBRUARY 24, 2023 - Giiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn's and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000.
HAMILTON, ON and BOSTON, Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha therapies ("TATs") as precision medicines...
MONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).
HAMILTON, ON and BOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.
MONTREAL (CANADA) – October 19, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) and Nanna Lüneborg, PhD, MBA, General Partner at Forbion.
HAMILTON, ON, Oct. 18, 2022 /CNW/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced that it has received funding from the Bill & Melinda Gates Foundation to find novel therapeutics that target tuberculosis...
MONTREAL (CANADA) – October 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (“NEA”).
MONTREAL (CANADA) – September 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announces the Company was awarded the 'Promising Health Biotech Company of the Year' Gold Leaf Award at the BIONATION Conference, currently held in Ottawa, Canada.
HAMILTON, ON, Sept. 21, 2022 /PRNewswire/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic collaboration with Evotec SE...
MONTREAL (CANADA) – September 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company's lead program.
HAMILTON, ON and BOSTON, Aug. 29, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in the Phase 1/2 study...
Jun 24, 2022 - NEW YORK – Illumina has acquired IDbyDNA, a company developing metagenomic technology for infectious disease testing and pathogen surveillance, GenomeWeb has learned today.
HAMILTON, ON and BOSTON, June 23, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) applications...
FREDERICK, Md., June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat serious immuno-inflammatory diseases with significant unmet medical needs, today announced favorable results from the Company's Phase 1 clinical program for VLX-1005, a novel 12-LOX inhibitor being developed...
MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately.
HAMILTON, Ontario & BOSTON, March 17, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2021 and provided an update on clinical and corporate developments.
MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.
TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021.
FREDERICK, Md., Feb. 23, 2022 /PRNewswire/ -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Lisa Beck as Chief Business Officer.
London, United Kingdom – Feb. 9, 2022 – Adeno-associated viruses (AAVs) are the safest and most effective gene delivery vehicles to drive long-term transgene expression in gene therapy. While animal studies have shown promising results, the translatability of AAVs into clinical settings has been partly limited due to their restricted gene packaging capacities, off-target transduction, and immunogenicity.
Montreal, Canada – 17 January 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder complications...
TORONTO & MONTREAL – January 13, 2022 – (BUSINESS WIRE)--Genesys Capital is pleased to announce the appointment of Dr. Maxime Ranger as a Venture Partner. Later this year, Dr. Ranger will transition from this role into the role of General Partner of Genesys Ventures IV LP.
HAMILTON, ON and BOSTON, Jan. 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the company has entered into a strategic research collaboration with Pepscan Therapeutics B.V. (Pepscan) to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors....
HAMILTON, Ontario and BOSTON, Jan. 11, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the company has entered into a strategic research collaboration with 48 Hour Discovery Inc....
HAMILTON, Ontario and BOSTON, Jan. 10, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the first targeted alpha therapy (TAT) candidate under the Company's collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN)...
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced...
HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer...
HAMILTON, ON and BOSTON, Sept. 28, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer...
MONTREAL – Giiant Pharma Inc., a Montreal biotech company developing gut-restricted drug therapeutics at the pre-clinical stage in gastroenterology, announced the expansion of its research leadership team with the appointment of Christophe Mellon, PhD.
MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial...
HAMILTON, ON and BOSTON and VANCOUVER, BC, Aug. 12, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase...
HAMILTON, ON and BOSTON, Aug. 10, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended June 30, 2021 and provided an update on clinical and corporate developments.
LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("PBT") has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for USD105M.
TORONTO, Aug. 04, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2021.
HAMILTON, ON and BOSTON, July 28, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines...
MONTREAL – Giiant Pharma Inc. announced today that is closed an additional financing of $750,000 from AQC Capital (AQC) and $500,000 from CQDM for a total of $1.25 million.
FREDERICK, Md., June 23, 2021 - Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Michael S. Hanna, MD, FACC, as chief medical officer.
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 23, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, Kedrion S.p.A (“Kedrion”) has exercised its option to acquire the remainder of the Company’s plasma-derived business under the terms of the Share Purchase Agreement entered into by the Company and Kedrion...
MONTREAL – Giiant Pharma Inc., a preclinical-stage biotech company developing gut-restricted drug therapeutics in gastroenterology, announced the appointment of a seasoned executive as an independent board member.
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the closing of a $16.6 million Series A financing. The round was led by Hatteras Venture Partners with participation from Genesys Capital...
HAMILTON, Ontario and BOSTON, June 14, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preliminary Phase 1 data from the single-dose portion of the study at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)...
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 4, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced today that the U.S. Food & Drug Administration (FDA) has approved Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia)...
HAMILTON, ON and BOSTON, June 2, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot...
MONTREAL – Giiant Pharma Inc., a Montreal-based preclinical-stage biotech company today announced the closing of US$11M (CAD$ 13.5M) million in Seed financing. The round was co-led by Amplitude Ventures and Genesys Capital, with participation from Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, Anges Québec, and other angel investors.
TORONTO, May 12, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2021.
HAMILTON, ON and BOSTON, May 11, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021 and provided an update on clinical and corporate developments.
TORONTO, May 06, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the signing of a multi-site imaging center agreement for TULSA-PRO® with Akumin Inc...
HAMILTON, ON and BOSTON, May 6, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada) to evaluate Fusion's lead candidate...
Metagenomics Innovator Expands Executive Team to Meet Growing Demand for its Actionable Infectious Disease Testing and Pathogen Surveillance Infectious disease continues to be a leading cause of illness, morbidity and mortality around the world. In the fight to better understand all pathogens, including the SARS-CoV-2 lineage and its mutations, IDbyDNA, the pioneer in Precision Metagenomics, is focused on broadening availability for its Next-Generation Sequencing (NGS) targeted products...
TORONTO, April 21, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2021 financial results after market close on Wednesday, May 12, 2021.
HAMILTON, ON and BOSTON, April 10, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting...
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy BodiesEVANSTON, Ill. - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders...
HAMILTON, ON and BOSTON, March 25, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2020 and provided an update on clinical and corporate developments.
SAN FRANCISCO MARCH 23, 2021 - As the battle against COVID-19 rages on, virus variants that can spread more easily – or for which vaccines and treatments are less effective – pose one of the most immediate threats. The widely used PCR and rapid antigen tests cannot detect these variants, allowing the virus to evolve in stealth mode...
TORONTO, March 03, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors.
HAMILTON, ON and BOSTON, March 2, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has entered into an asset purchase agreement (APA) to acquire Ipsen's (Euronext: IPN; ADR; IPSEY) intellectual property and assets...
TORONTO, March 02, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2020.
SUDBURY, Ontario - Flosonics Medical, a Canadian medical device company focused on non-invasive hemodynamic monitoring, announced the close of a $14 million USD funding round led by Arboretum Ventures. The financing also included participation from existing investors iGan Partners and Genesys Capital...
SAN FRANCISCO, Jan. 20, 2021 - Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae...
Today, IDbyDNA, the company revolutionizing the use of metagenomics to improve health by decoding the unknown, is announcing its participation in the “Detect It with Gene Editing Technologies” (DIGET) program funded by the United States Defense Advanced Research Projects Agency (DARPA)...
SOUTH SAN FRANCISCO, Calif. and SALT LAKE CITY, Jan. 07, 2021 - Today, CareDx, the leading partner in transplant care, and IDbyDNA, the company revolutionizing the use of precision metagenomics, announced an exclusive partnership focused on the development of metagenomic infectious disease testing specific to transplant patients...
MONTREAL (CANADA) – January 07, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease (RPD) designation to the Company’s lead compound, INV-101, for the treatment of Prader-Willi syndrome (PWS)...
MINNEAPOLIS, Jan. 6, 2021 - Functional Neuromodulation announced today that it has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for the Vercise™ Deep Brain Stimulation (DBS) Systems, developed and manufactured by Boston Scientific Corporation...
EVANSTON, Ill. - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorder today announced that in December it recommenced patient recruitment and screening in a Phase 2 study of NYX-2925...
TORONTO, Dec. 21, 2020 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combireal-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue...
HAMILTON, ON and BOSTON, Dec. 10, 2020 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals precision medicines, today announced that the first patient has been dosed in the multi-dose portion of the Phase 1 study evaluating [225Ac]-FPI-1434 (FPI-1434) in patients wiadvanced solid tumors...
MONTREAL (CANADA) – November 30, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. CrateMD, FCCP as its Chief Medical Officer...
TORONTO, Nov. 30, 2020 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administratio“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma.
MONTREAL (CANADA) – November 30, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome...
HAMILTON, ON and BOSTON, Nov. 10, 2020 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals precision medicines, today announced financial results for the third quarter ended September 30, 2020 and provided an update on clinical and corporate developments.
TORONTO, Nov. 05, 2020 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combireal-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue...
SAN FRANCISCO, Nov. 5, 2020 - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter endSeptember 30, 2020.
Fusion Pharmaceuticals (NASDAQ: FUSN), a Genesys originated company, announced a global collaboration with AstraZeneca to co-develop next generation targeted alpha radiopharmaceuticals and radiopharmaceutical combination therapies...
MONTREAL (CANADA), September 08, 2020 - Inversago Pharma Inc. today announced it has secured a US$35 million (€32 million) Series B financing round led by Forbion, with co-investment from the Fonds de solidarité FTQ, and strong participation from existing investors Genesys Capital.
SAN FRANCISCO, March 17, 2020 – IDbyDNA Inc., a metagenomics technology company setting a standard for detection, identification and interpretation of microorganisms and their role in human health, today announced a global strategic partnership with Illumina, Inc. (Nasdaq: ILMN), to bring comprehensive next-generation sequencing (NGS) based workflows to the global microbiology market....
TORONTO, April 04, 2019 - Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control...
Apr. 2, 2019 - At US$105 million, this is one of the largest private financings in the history of the Canadian Life Sciences sector. The round was co-led by OrbiMed Advisors and Varian Medical Systems...
SAN FRANCISCO, Feb. 19, 2019 - Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018...
BOSTON, Massachusetts and HAMILTON, Ontario—February 19, 2019 - Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors...
MONTREAL (CANADA) – 25 July 2018 – Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform as a potent treatment for targeted diseases...
May 23, 2018 – Aptinyx, which is developing therapeutics for neurological disorders, filed on Wednesday with the SEC to raise up to $80 million in an initial public offering...
EVANSTON, IL – May 22, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator...
TORONTO, May 21, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power of directional and focused ultrasound technology...
EVANSTON, IL., May 17, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that it has appointed Robert J. Hombach, a healthcare industry veteran, to its board of directors.
SAN FRANCISCO, May 9, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the first quarter ended March 31, 2018. Based on the growing momentum in test volume and substantial revenue growth, the company is increasing its volume guidance...
SAN FRANCISCO, March 28, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae...
MISSISSAUGA, ON, Feb. 28, 2018 /CNW/ - Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company") is pleased to announce today that it has entered into a revised agreement with a syndicate of underwriters, led by Canaccord Genuity Corp. (the "Underwriters"), pursuant to which the Underwriters will purchase, on a bought deal basis...
SAN FRANCISCO, Feb. 12, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.
TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. today announced the completion of patient enrollment in the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study...pivotal study designed to further evaluate the safety and efficacy of TULSA-PRO® to ablate prostate tissue in patients with localized, organ-confined prostate cancer.
SUDBURY ON — Jan. 29, 2018 — FloSonics Medical, a Canadian medical device company headquartered in Greater Sudbury, Ontario, has secured $5 million in a funding round led by Toronto’s iGan Partners. FloSonics Medical is focused on developing non-invasive sensors to improve the management of critically ill patients.
HAMILTON, ON, Jan. 9, 2018 /PRNewswire/ - Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, today announced that it has completed a round of financing...
Jan. 8, 2018 - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced preliminary full-year 2017 results that demonstrate continued strong momentum, with volume and revenue more than doubling compared to 2016 results. Preliminary financial results for 2017 include...
TORONTO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power...
EVANSTON, Ill., Dec 18, 2017 /PRNewswire/-- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding clinical-stage pipeline...
Evanston, Ill., Dec 7, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Fast Track designation, new data, and initiation of Phase 1 clinical development for its second clinical candidate to modulate N-methyl-D-aspartate (NMDA) receptors, NYX-783, in post-traumatic stress disorder (PTSD). The data were presented at the annual meeting of the American College of Neuropsychopharmacology (ACNP)...
HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD...
NORWOOD, Mass., July 21, 2017 (BUSINESS WIRE) Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal Inc. develops and provides point-of-care blood diagnostic systems for healthcare enterprises, including the epoc® Blood Analysis System, a handheld, wireless testing solution. Financial details of the transaction are not being disclosed...
HAMILTON, ON, February 23, 2017 - Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson & Johnson Innovation - JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital...
TORONTO, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) ("Profound" or the "Company"), an emerging medical device company focused on prostate care, today announced the appointment of Kenneth Galbraith to its Board of Directors.
January 09, 2017 - Invitae Corporation (https://www.invitae.com/en) (NYSE:NVTA), one of the fastest growing genetic information companies, today announced that Sean George, Ph.D., its co-founder and current president and chief operating officer, has been named chief executive officer for the company.
January 06, 2017 - Invitae Corporation (https://www.invitae.com/en) (NYSE:NVTA), one of the fastest growing genetic information companies, announced initial fourth quarter and full-year 2016 results, showing 200% year-over-year growth in billable test volume, driven by milestones including a major expansion of its test menu to more than 1,100 genes and agreements...
November 17, 2016 - SAN FRANCISCO -- (BUSINESS WIRE) -- Invitae Corporation (NYSE:NVTA) today announced the pricing of an underwritten public offering of 7,333,333 shares of its common stock at a price to the public of $6.00 per share.
TORONTO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or the "Company") (TSX-V:PRN) today announced that it has completed its previously announced bought deal offering of 15,820,000 common shares of the Company ("Common Shares") at a price of $1.10 per Common Share (the "Offering") for gross proceeds of...
TORONTO, Sept, 22, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company") a medical device company focused on prostate care, today announced that the first patient has been treated in the TACT Pivotal Clinical Trial at Vanderbilt University Medical Center in Nashville, TN.
TORONTO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company"), an emerging medical device company focused on prostate cancer care, today announced the appointment of Arun Menawat, Ph.D. as its new Chief Executive Officer.
Evanston, Ill., July 13, 2016 - Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurologic disorders, today announced the initiation of dosing in a Phase 1, first-in-human study for its lead therapeutic candidate, NYX 2925.
TORONTO and AMSTERDAM, Netherlands, May 11, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN), a Toronto-based medical device company and Royal Philips (NYSE:PHG) (AEX:PHIA), a leading health technology company, today announced that they have signed a sales and marketing agreement that will advance the commercial launch of Profound's TULSA-PRO, a minimally...
